This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Clinical and Economic Impact of an Electronic Medical Record Interfaced Decision Support System Reinforced With Patient Specific Pharmacogenetic Data for Minimizing Severe Drug-Drug Interactions (DDI+)

This study has been completed.
Information provided by (Responsible Party):
Leumit Health Services Identifier:
First received: January 9, 2013
Last updated: October 20, 2014
Last verified: October 2014
Leumit Health Services, an health maintenance organization operating in Israel, will incorporate a web-based, decision support system for handling drug-drug interactions and drug information, termed DDI+ reinforced with patient specific pharmacogenetic data. The investigators hypothesize that implementing such a system will reduce health-care expenditures (e.g., hospital admissions, referrals to ERs, Imaging procedures).

Condition Intervention
Healthcare Other: DDI+ System and Pharmacogenetic Data

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Clinical and Economic Impact of a Web Based, Electronic Medical Record Interfaced Electronic Decision Support System Incorporating Pharmacogenetic Evaluation for Physicians Intended, Mainly for Drug-drug Interaction. A Controlled Study in an Ambulatory Health Maintenance Organization Population

Resource links provided by NLM:

Further study details as provided by Leumit Health Services:

Primary Outcome Measures:
  • Hospital Admissions [ Time Frame: up to 12 month post initiation ]

Enrollment: 973
Study Start Date: January 2013
Study Completion Date: October 2014
Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DDI+ and Pharmacogenetic data
DDI+ System and Pharmacogenetic data
Other: DDI+ System and Pharmacogenetic Data
No Intervention: Standard Care


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Number of chronic concomitant drugs ≥5
  • treated with 1 or more drugs with a well established interaction with 1 or more of the following CYP450 enzymes: 2c9, 2c19, 2d6

Exclusion Criteria:

  • Patients diagnosed with HIV/AIDS, and/or viral hepatitis B or C
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01765621

Leumit Health Services
Tel-Aviv, Israel
Sponsors and Collaborators
Leumit Health Services
  More Information

Responsible Party: Leumit Health Services Identifier: NCT01765621     History of Changes
Other Study ID Numbers: LHS022013
Study First Received: January 9, 2013
Last Updated: October 20, 2014

Keywords provided by Leumit Health Services:
health care expenditure
drug drug interactions
electronic decision support systems
Potential Reduction processed this record on September 20, 2017